HMGCR; | |
TP53; | |
MAPT; | |
SMN1;SMN2; |
Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
---|---|---|---|---|
Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
Methyl-lysine/arginine binding protein | SMN1;SMN2 | Survival motor neuron protein | Q16637 | CHEMBL1293232 |
Oxidoreductase | HMGCR | HMG-CoA reductase | P04035 | CHEMBL402 |
Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|
MF | GO:0005488; binding | GO:0051721; protein phosphatase 2A binding | 5.440E-08 | 1.184E-03 | HMGCR, MAPT, TP53 |
MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 4.823E-07 | 3.501E-03 | CYP1A2, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 1.205E-06 | 6.562E-03 | CYP1A2, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0009820; alkaloid metabolic process | 1.687E-06 | 7.349E-03 | CYP1A2, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0006720; isoprenoid metabolic process | 5.217E-06 | 1.154E-02 | CYP1A2, CYP3A4, HMGCR |
BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 5.300E-06 | 1.154E-02 | CYP1A2, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 5.300E-06 | 1.154E-02 | CYP1A2, CYP3A4 |
MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 2.028E-05 | 3.681E-02 | CYP1A2, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0006706; steroid catabolic process | 2.605E-05 | 4.051E-02 | CYP1A2, CYP3A4 |
BP | GO:0009987; cellular process | GO:0034605; cellular response to heat | 7.913E-05 | 1.014E-01 | MAPT, TP53 |
MF | GO:0005488; binding | GO:0019825; oxygen binding | 7.913E-05 | 1.014E-01 | CYP1A2, CYP3A4 |
CC | GO:0016020; membrane | GO:0005789; endoplasmic reticulum membrane | 1.939E-03 | 4.444E-01 | CYP1A2, CYP3A4, HMGCR |
CC | GO:0044464; cell part | GO:0030673; axolemma | 4.960E-03 | 6.586E-01 | MAPT |
Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|---|
09100 Metabolism | 09103 Lipid metabolism | hsa00591 | Linoleic acid metabolism | 3.034E-05 | 1.517E-03 | CYP1A2, CYP3A4 |
09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 1.231E-04 | 1.627E-03 | CYP1A2, CYP3A4 |
09100 Metabolism | 09108 Metabolism of cofactors and vitamins | hsa00830 | Retinol metabolism | 1.547E-04 | 1.627E-03 | CYP1A2, CYP3A4 |
09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00982 | Drug metabolism - cytochrome P450 | 1.744E-04 | 1.627E-03 | CYP1A2, CYP3A4 |
09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 1.953E-04 | 1.627E-03 | CYP1A2, CYP3A4 |
09150 Organismal Systems | 09154 Digestive system | hsa04976 | Bile secretion | 1.847E-04 | 1.627E-03 | HMGCR, CYP3A4 |
09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 2.464E-04 | 1.760E-03 | CYP1A2, CYP3A4 |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04010 | MAPK signaling pathway | 2.348E-03 | 1.305E-02 | MAPT, TP53 |
Unclassified | Unclassified | hsa01100 | Metabolic pathways | 4.116E-03 | 2.058E-02 | CYP1A2, HMGCR, CYP3A4 |
09100 Metabolism | 09110 Biosynthesis of other secondary metabolites | hsa00232 | Caffeine metabolism | 1.499E-03 | 9.370E-03 | CYP1A2 |
ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
---|---|---|---|
G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | MAPT; |
C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53; |
G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | MAPT; |
S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53; |
C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | TP53; |
H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53; |
C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | TP53; |
C00-D49: Neoplasms | Hematological malignancies | C81-C86 | TP53; |
C00-D49: Neoplasms | Colorectal cancer | C18-C21 | TP53; |
C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TP53; |
C00-D49: Neoplasms | Solid tumours | C00-D48 | TP53; |
G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | MAPT; |
C00-D49: Neoplasms | Cancer | C00-C96 | TP53; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | MAPT; |
I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53; |